Cargando…
High expression of PD-1 ligands is associated with kataegis mutational signature and APOBEC3 alterations
Immunotherapy with checkpoint inhibitors, such as antibodies blocking the programmed cell-death receptor-1 (PD-1), has resulted in remarkable responses in patients having traditionally refractory cancers. Although response to PD-1 inhibitors correlates with PD-1 ligand (PD-L1 or PD-L2) expression, P...
| Autores principales: | , , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
Taylor & Francis
2017
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5384346/ https://www.ncbi.nlm.nih.gov/pubmed/28405512 http://dx.doi.org/10.1080/2162402X.2017.1284719 |